Listen on the go
CORRECT!
Next question
touchENDOCRINOLOGY touchENDOCRINOLOGY
Liver Disorders

Quentin Anstee, Digital NAFLD Summit 2021: Exciting Advances and New Research into the Management of Non-alcoholic Fatty Liver Disease

Share this Video
Copy Link
Published Online: Oct 7th 2021

touchENDOCRINOLOGY joins Prof. Quentin Anstee (Newcastle University, UK) at the Digital NAFLD Summit 2021 to discuss his highlights from the conference and new, exciting developments in the field.

Questions
1. Please summarise the prevalence of non-alcoholic fatty liver disease (NAFLD) and the clinical unmet needs in this area? (0:20)
2. What are the current most exciting advances and new research in this field? (1:00)

Disclosures: Quentin Anstee has no conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed in coverage of the Digital NAFLD Summit 2021.

Related Videos In Liver Disorders
Liver Disorders
Developed by Touch
Rifaat Safadi, EASL 2023: CM-101 for the treatment of non-alcoholic steatohepatitis – clinical endpoints and next steps
Watch Time: 5 mins

CM-101, a CCL24 neutralizing antibody, has been recently studied in patients with non-alcoholic steatohepatitis in a phase IIa proof-of-concept study. We caught up with Prof Rifaat Safadi (The Liver Institute, Hadassah Medical Organization, Hadassah Hebrew University Medical Center, Jerusalem, Israel) to discuss the primary and secondary endpoints and how well they were achieved, and the […]

Liver Disorders
Developed by Touch
Rifaat Safadi, EASL 2023: CM-101 for the treatment of non-alcoholic steatohepatitis – aims and design
Watch Time: 4 mins

CM-101, a CCL24 neutralizing antibody, has been recently studied in patients with non-alcoholic steatohepatitis in a phase IIa proof-of-concept study. In this touchENDOCRINOLOGY interview, we caught up with Prof Rifaat Safadi (The Liver Institute, Hadassah Medical Organization, Hadassah Hebrew University Medical Center, Jerusalem, Israel) to discuss the mechanism of action of CM-101, and the aims, […]

Liver Disorders
Developed by Touch
Paul Brennan: International NASH day 2023
Watch Time: 4 mins

International NASH Day (NASH Day) takes place on the 8th June 2023. It is a public education campaign launched in June 2018 to raise visibility and urgency around fatty liver disease and its more advanced form, nonalcoholic steatohepatitis (NASH), which affects more than 115 million people around the world. We were delighted to talk with […]

Trending In Liver Disorders:

Rifaat Safadi, EASL 2023: CM-101 for the treatment of non-alcoholic steatohepatitis – clinical endpoints and next steps
Liver Disorders
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72